Alphamab Oncology

English 中文简体中文繁体

KN026 was Granted Breakthrough Therapy Designation by CDE

KN026 is expected to become the first anti-HER2 treatment for second-line gastric cancer where HER2-targeted therapy has failed
Alphamab Oncology Announces New Data from Multiple Studies of KN046 with Lung Cancer and Thymic Carcinoma at ESMO

the results of four studies of PD-L1/CTLA-4 bispecific antibody KN046 were presented at ESMO
Alphamab Oncology updated data from two studies of KN026 in combination with docetaxel for HER2-positive breast cancer at ESMO

the results of two studies of HER2 bispecific antibody KN026 were presented at ESMO

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : Developing differentiated, clinically valuable, and internationally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

Learn More

Proprietary Platforms
Innovative Pipeline
Biologics Manufacturing

WORLD-CLASS BISPECIFIC, ADC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. Alphamab Oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

Learn More

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

Learn More

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Learn More

Company

Overview

Board of Directors

Partnering

Core competence

Technology

Bispecific

Proprietary ADC Platform

Mix-mAb

Publications

Pipeline

Overview

Envafolimab(KN035)

KN046

KN026

JSKN003

KN026+KN046

KN019

KN052

Investors

Information Disclosure

Corporate Governance

Stock Information

IR Contacts

Email Subscription

News

Press Release

Media Report

Career

Corporate Culture

Job Opportunities

Contact Us

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable

Our Vision : Developing differentiated, clinically valuable, and internationally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

WORLD-CLASS BISPECIFIC, ADC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. Alphamab Oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

VISION, MISSION AND CORE VALUES

Our Mission : To make cancer manageable and curable Our Vision : Developing differentiated, clinically valuable, and internationally competitive new drugs Our Core Values : Innovation, Ownership, Integrity, Quality, Growth

WORLD-CLASS BISPECIFIC, ADC AND MIX-MAB PLATFORMS

In complex diseases, such as cancer and viral infection, multiple signaling pathways or mechanisms are involved. Alphamab Oncology has developed several proprietary technical approaches to provide innovative solutions to address this growing trend in the development of modern biotherapeutics.

INNOVATIVE PIPELINE WITH SIGNIFICANT POTENTIAL AND MITIGATED DEVELOPMENT RISK

Leveraging its proprietary technology platforms, Alphamab Oncology has developed an exciting pipeline with clear differentiation and global competitiveness.

STATE OF ART cGMP MANUFACTURING WITH A SOLID TRACK RECORD

The production of biologics, such as antibody drugs, is a complex, lengthy and costly process. We have established our own cGMP production facilities with strong in house expertise to address the manufacturing issues.

Our Mission : To make cancer manageable and curable

Our Vision : Developing differentiated, clinically valuable, and internationally competitive new drugs

Our Core Values : Innovation, Ownership, Integrity, Quality, Growth